Tvardi Therapeutics (NASDAQ:TVRD) Downgraded to Sell Rating by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

TVRD has been the subject of several other reports. Piper Sandler cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 22nd. Finally, Raymond James Financial lowered shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Stock Performance

NASDAQ:TVRD opened at $4.14 on Monday. The company has a market cap of $38.83 million, a price-to-earnings ratio of -0.43 and a beta of 0.11. The stock’s fifty day moving average price is $4.30 and its two-hundred day moving average price is $19.54. Tvardi Therapeutics has a 52-week low of $3.74 and a 52-week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. Tvardi Therapeutics had a negative return on equity of 282.16% and a negative net margin of 585.37%.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TVRD. Geode Capital Management LLC bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $2,617,000. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics during the second quarter worth about $39,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at approximately $92,000. Marshall Wace LLP bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at approximately $583,000. Finally, Slate Path Capital LP bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at approximately $16,427,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.